Merck Q4 2022 Earnings February 2, 2023 -- 1 of 36 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 36 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 36 -- Strategy & Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 36 -- Delivered on our key strategic priorities in 2022 5 Achieved strong commercial and financial performance Advanced the pipeline to meet patient unmet need Executed on strategic business development to enhance pipeline Created long-term value for patients and shareholders -- 5 of 36 -- Exceptional 2022 sales and underlying earnings growth1 6 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have been recast to include $4.2 billion of incremental R&D expenses, which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, which reduced EPS by $0.65. For 2022, non-GAAP results include $690 million of R&D expense, or an estimated $0.22 of negative impact to EPS related to an asset acquisition, and collaboration and licensing agreements. 3. GAAP EPS of $1.18. $41.5B +6% $48.7B +17% GUIDANCE RANGE $57.5B-$58.5B $13.8B +2% 4Q Worldwide Sales $1.62 -10% 4Q Non-GAAP EPS2,3 2020 2021 2022 $41.5B +6% $48.7B +17% 2020 2021 2022 $2.97 $5.37 Full Year Revenue Full Year Non-GAAP EPS2 $59.3B +22% $7.48 -- 6 of 36 -- Advancing and augmenting pipeline across multiple therapeutic areas in Q4 7 Oncology Cardiovascular • Merck to present data for sotatercept and MK-0616, oral macrocyclic peptide PCSK9 inhibitor, at ACC.23/WCC • Merck to host investor event on March 6 th to discuss these results • Announced positive top line results for the Phase 2 trial evaluating KEYTRUDA in combination with mRNA-4157/V940, an investigational personalized mRNA therapeutic cancer vaccine in adjuvant treatment of patients with stage III/IV melanoma following complete resection • Received FDA approval for KEYTRUDA for the adjuvant treatment of adult patients with stage IB (T2a >=4 cm), II or IIIA non-small cell lung cancer following resection and platinum-based chemotherapy based on KN-091 Vaccines • Merck collaborator Instituto Butantan (IB) announced positive topline results from IB’s Phase 3 dengue vaccine candidate. Results to inform next steps for V181 program1 Business Development • Augmented pipeline with new candidates from recent business development transactions, including: o Collaborations with Moderna and Kelun- Biotech o Acquisition of Imago • In 2023, expect four Phase 3 trial starts from programs added in 2022 through business development 1. Both Merck and IB’s investigational vaccines are derived from materials licensed from the U.S. National Institutes of Health and both institutions are evaluating formulations analogous to the NIH TV003 formulation. -- 7 of 36 -- Enhance durable growth drivers Deploy cash flow to value-enhancing BD Leverage leadership in oncology Advance pipeline across key therapeutic areas Building a sustainable engine to drive success into the next decade 8 New combinations and coformulations New delivery mechanisms New mechanisms of action outside of immuno-oncology Cardiometabolic Vaccines Neuroscience Infectious Disease/ Immunology Additional immuno- oncology approaches Ample balance sheet capacity Disciplined approach Pursuing the best external science Vaccines Animal Health -- 8 of 36 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 36 -- Merck achieved exceptional 2022 financial performance 1 10 WORLDWIDE SALES2 $59.3B+22% growth +26% ex-exchange +15% ex-exchange, LAGEVRIO4 NON-GAAP EPS33,5 $7.48+39% growth +43% ex-exchange Merck 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue; 3. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the press release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in 2022. 4. Excludes impact of foreign exchange and LAGEVRIO sales of $5.7B. 4. GAAP EPS of $5.71. -- 10 of 36 -- Strong Q4 performance across Human Health and Animal Health 11 Merck WORLDWIDE SALES1,2 $13.8B+ 2% growth +8% ex-exchange $12.2B +1% growth +9% ex-exchange Human Health $1.2B -2% growth +6% ex-exchange Animal Health 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue -- 11 of 36 -- Oncology: KEYTRUDA drives continued growth 12 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $5.5B increased 26% year-over-year, driven by strong global demand and expansion into new indications – In the U.S., growth of 27% reflects strong growth across all key tumor types, especially in earlier-stage cancers such as high-risk, early- stage TNBC – Expect to launch earlier stage NSCLC indication based on recent FDA approval of KEYNOTE-091 study – Ex-U.S., 24% increase driven by continued global uptake in metastatic indications, such as NSCLC, H&N and RCC • Strong uptake from recent launches in high-risk, early-stage TNBC and RCC $4.2B +20% $3.4B +31% $5.3B +30% 4Q20 4Q21 4Q22 $4.6B +16% $4.0B +27% $5.5B +26% -- 12 of 36 -- Oncology: Robust performance across broad portfolio • Lynparza 1 sales increased 14%, with growth driven by continued demand in adjuvant treatment of certain patients with gBRCAm, HER2-negative high-risk early- stage breast cancer • Lenvima 2 sales grew 9% driven by increased uptake in advanced RCC and advanced endometrial cancer in the U.S. • WELIREG continues to perform in line with expectations providing a treatment option for patients with certain VHL-associated tumors $248M +34% $178M +62% $275M +17% $181M +15% $151M +57% $231M +33% 13 Growth rates exclude the impact of foreign exchange. 1 In collaboration with AstraZeneca; 2 In collaboration with Eisai 4Q20 4Q21 4Q22 4Q20 4Q21 4Q22 $268M +33% $206M +53% $292M +14% $206M +31% $158M +26% $216M +9% -- 13 of 36 -- Vaccines: Gardasil growth driven by strong global demand 14 • GARDASIL sales of $1.5B increased 6% year-over-year primarily driven by strong underlying demand outside the U.S. – Ex-U.S., reflects demand driven growth, particularly in China – U.S. sales declined primarily due to CDC purchasing patterns • Pediatric launch of VAXNEUVANCE off to an encouraging start; sales benefitted from inventory stocking $1.2B +78% $656M -24% $1.7B +40% 4Q20 4Q21 4Q22 $1.5B +50% $998M +41% $1.5B +6% Growth rates exclude the impact of foreign exchange. -- 14 of 36 -- Hospital: Strong global demand across key products 15 • BRIDION sales of $441M increased 7% primarily due to greater share among neuromuscular blockade reversal agents and increase in surgical procedures • PREVYMIS sales grew 28%, driven by continued strong global demand • ZERBAXA benefited from completion of global resupply which started in Q4 2021 $387M +67% $224M -18% $426M +15% 4Q20 4Q21 4Q22 $436M +24% $355M +13% $441M +7% $93M +41%$63M +67% $103M +18% 4Q20 4Q21 4Q22 $100M +27% $80M +57% $118M +28% Growth rates exclude the impact of foreign exchange. -- 15 of 36 -- Animal Health: Solid growth driven by livestock 16 • Animal Health sales increased 6% to $1.2B, reflecting strategic price actions and volume growth – Livestock sales grew 12% due to increased demand in ruminants and poultry products – Companion Animal sales decreased 5% due to supply challenges for certain vaccines and a reduction in vet visits in October, which improved during the quarter $1.5B +27% $1.1B +3% $1.5B +5% 4Q20 4Q21 4Q22 $1.3B +8% $1.2B +6% $1.2B +6% Growth rates exclude the impact of foreign exchange. -- 16 of 36 -- Q4 2022 continuing operations non-GAAP financial results summary1 Q4 2022 Q4 2021 Change Change Ex-FX Sales $13.8 $13.5 +2% +8% Non-GAAP Gross Margin 75.7% 74.8% +0.9pts +0.3pts Non-GAAP Operating Expenses 2 $5.7 $5.3 +8% +12% Non-GAAP Tax Rate 15.6% 4.3% +11.3pts N/A Non-GAAP EPS 3 $1.62 $1.81 -10% -7% $ in billions, except EPS amounts 17 1. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the press release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in 2022. 2. Non-GAAP results include $690 million of R&D expense, or an estimated $0.22 of negative impact to EPS, related to an asset acquisition, and collaboration and licensing agreements 3. Q4 2022 GAAP EPS of $1.18. -- 17 of 36 -- Merck provides full-year 2023 guidance 1. GAAP Gross Margin Rate: ~73%. 2. GAAP Operating Expenses: $23.3 to $24.3 billion. 3. GAAP Tax Rate: ~17-18% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q4 2022 earnings release 5. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Guidance Key Assumptions Revenue $57.2B to $58.7B -4% to -1% (-2% to +1% ex-FX) • Includes approximately $1B of LAGEVRIO revenue • Ex-LAGEVRIO, growth of 5% to 8% (7 to 10% ex-FX) • Assumes ~2% FX headwind Non-GAAP Gross Margin Rate 1 ~77.0% Non-GAAP Operating Expenses 2 $23.1B to $24.1B • Includes $1.4B of upfront R&D expense related to acquisition of Imago Biosciences and expansion of collaboration with Kelun Biotech Other (Income) / Expense ~$250M of income • Assumes no pension settlement cost as well as an expectation of higher interest income and higher joint venture equity income Tax Rate3 ~17.0%-18.0% • Assumes unfavorable impact due to the R&D capitalization provision, as well as ~1% unfavorable impact related to Imago Shares Outstanding ~2.55B GAAP EPS $5.86 to $6.01 Non-GAAP EPS4,5 $6.80 to $6.95 • Reflects upfront R&D expense $0.53 for Imago Biosciences and Kelun Biotech • Assumes ~4% FX headwind 18 -- 18 of 36 -- Key modeling considerations for 2023 19 Other Revenue • Expect strong growth driven by robust global demand, particularly in ex-U.S. markets • Increased ability to supply positions us well to support significant demand now and in the future • Expect significant decline, resulting from smaller planned benefit from revenue hedges following U.S. dollar strength in 2022 o Resulted in an ~$800M benefit in 2022 • Reflects discontinuation of third- party manufacturing sales to Johnson and Johnson GARDASIL Other (Income) / Expense and Tax Rate • Other Income assumes no pension settlement cost; expect higher interest income and joint venture equity income • Tax Rate assumes unfavorable impact of R&D capitalization provision and approximate 1 ppt unfavorable impact related to the Imago transaction -- 19 of 36 -- 20 Continue to prioritize investments in our pipeline and business to realize value of near- and long-term opportunities $2.6 $1.1 $1.7 $0.3 $0.0 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase $ Billions 1 1. Reflects Q4 spend Remain committed to balanced capital allocation strategy Capital allocation order of priority -- 20 of 36 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 21 of 36 -- 22 Working to help transform the landscape of cancer treatment by focusing on earlier stages of disease Advancing our collaboration with Moderna to leverage mRNA technology with KEYTRUDA to target the unique mutational signature of each patient’s tumor in melanoma and other tumor types KEYTRUDA Immunotherapy that increases the ability of the body’s immune system to help detect and fight tumor cells mRNA-4157/V940 Designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor Making progress in the treatment of earlier stage non-small cell lung cancer through various clinical trials APPROVED PHASE III • KEYNOTE-091: Received FDA approval for KEYTRUDA for adjuvant treatment of adult patients with stage IB (T2a >=4 cm), II or IIIA NSCLC following resection and platinum-based chemotherapy • KEYNOTE-671: Evaluating KEYTRUDA with platinum doublet chemotherapy as neoadjuvant followed by adjuvant therapy for patients with resectable stage II, IIIA and IIIB NSCLC • KEYNOTE-867: Evaluating KEYTRUDA in patients undergoing stereotactic body radiotherapy with unresected stage I or II NSCLC • KEYLYNK-012: Evaluating KEYTRUDA in combination with Lynparza1 in stage III disease 1 In collaboration with AstraZeneca -- 22 of 36 -- 23 Advancing our broader oncology portfolio Hematology Tissue Targeting Therapies Ex-U.S. Approvals Positive Data Readouts • In Europe: – Received approval for Lynparza1 in combination with abiraterone and prednisone or prednisolone for the treatment of certain patients with mCRPC based on PROpel • In China: – Received approval for KEYTRUDA in neoadjuvant / adjuvant high-risk, early- stage TNBC based on KN-522 – Received approval for KEYTRUDA in hepatocellular carcinoma based on KN-394 • Announced acquisition of Imago Biosciences: – Lead candidate bomedemstat a potentially first-in-class orally available lysine-specific demethylase 1 inhibitor (LSD-1) • Presented data at American Society of Hematology Meeting for: – favezelimab (anti-LAG3) – zilovertamab vedotin (ROR-1) – nemtabrutinib (BTKi) – KEYTRUDA • Padcev2: FDA accepted sBLA for Keytruda to be used in combination with Padcev, an ADC targeting Nectin-4, for 1L treatment of certain patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin- containing chemotherapy • Kelun-Biotech: Expanded collaboration with up to 7 additional preclinical antibody drug conjugate candidates • PeptiDream: Expanded ongoing collaboration for the discovery and development of peptide drug conjugates • KEYNOTE-966: Announced positive Phase III results evaluating KEYTRUDA in combination with chemotherapy in 1L treatment of advanced or unresectable biliary tract cancer • KEYNOTE-859: Announced positive Phase III results evaluating KEYTRUDA in combination with chemotherapy in HER2- negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma 1. In collaboration with Astra Zeneca 2. In collaboration with Astellas and Seagen. Padcev is a registered trademark of Seagen and Agensys. -- 23 of 36 -- 24 Focusing on important unmet medical needs through vaccine development programs • Receiving positive feedback from physicians following launch of VAXNEUVANCE in the pediatric setting • VAXNEUVANCE offers strong immunogenicity, including in the first year of life where incidence of IPD is greatest within the healthy pediatric population Pneumococcal Disease Chart Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs). Active Bacterial Core Surveillance (ABCs) report emerging infections program network streptococcus pneumoniae, 2019. Available: SPN Surveillance Report 2019.pdf (cdc.gov). Source: Epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US children, Ryan Gierke, MPH. Advisory Committee on Immunization Practices, February 24 th , 2022. • Collaborating with Instituto Butantan (IB) to conduct a detailed analysis of IB’s positive Phase 3 data in order to determine further clinical development of Merck’s vaccine candidate, V181 V181 is being investigated to help provide, in a single dose, protection against all four dengue serotypes regardless of prior exposure to dengue Dengue Invasive Pneumococcal Disease -- 24 of 36 -- 25 Recent data published on cancer incidence Among women ages 20 to 24, cervical cancer incidence rates declined by a total of … 65% from 2012 through 2019. 1 • We, along with others in the industry, are making a real impact in our goal to help reduce cancer incidence • American Cancer Society published its annual report on cancer facts and trends • Reinforces our commitment to bringing forward treatment and prevention options to help patients - American Cancer Society Cervical Cancer 1. Cancer statistics, 2023, Rebecca L. Siegel, CA Cancer J Clin. 2023; 73:17–48 -- 25 of 36 -- 26 Significant advancements across our broader pipeline and portfolio • Granted conditional marketing authorization for LAGEVRIO by China's National Medical Products Administration • Under Emergency Use Authorization, LAGEVRIO remains an important treatment option as the COVID- 19 pandemic continues to evolve COVID-19 Cardiovascular At ACC.23/WCC on March 6th, Merck to: • Present results from Phase 3 STELLAR study evaluating sotatercept for treatment of pulmonary arterial hypertension • Present data from Phase 2 study evaluating MK-0616, oral macrocyclic peptide PCSK9 inhibitor, for treatment of hypercholesterolemia • Host live investor event -- 26 of 36 -- Strong progress across our pipeline throughout 2022 27 1. Both Merck and IB’s investigational vaccines are derived from materials licensed from the U.S. National Institutes of Health and both institutions are evaluating formulations analogous to the NIH TV003 formulation. 2. nucleoside reverse transcriptase translocation inhibitor • VAXNEUVANCE: Received approval in the pediatric setting • V116: Received Breakthrough Therapy Designation and advanced into Phase 3 trials for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults • V181: Merck collaborator Instituto Butantan (IB) announced positive topline results from IB’s Phase 3 dengue vaccine candidate. Results to inform next steps for V181 program1 Cardiometabolic Infectious Disease Vaccines • Sotatercept: Announced positive topline results for Phase 3 STELLAR trial in PAH • MK-0616: Completed Phase 2 trial in patients with hypercholesterolemia • MK-2060: Received Fast Track designation for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD • MK-5475: Initiated Phase 2 study in patients with PH-COPD • Islatravir: Reinitiated development program in the HIV treatment setting • MK-8527: Initiated Phase 1b study of internal novel NRTTI 2 for HIV PrEP • LAGEVRIO: Initiated Phase 2 trial for the treatment of RSV Oncology • KEYTRUDA: – Received approval for advanced endometrial cancer that is MSI-H or dMMR (KN-158) – Received approval for KN-091 for adjuvant treatment of adult patients with stage IB (T2a >= 4cm), II or IIIA NSCLC following resection and platinum-based chemotherapy – Announced positive topline results for HER2- locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma (KN-859) • Lynparza: Received approval for adjuvant treatment of adults with gBRCAm, HER2- high-risk early breast cancer (OlympiA) • MRNA-4157/V940: Announced positive topline results for Phase 2b trial in adjuvant treatment in patients with stage III/IV melanoma following complete resection -- 27 of 36 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 28 of 36 -- Appendix 29 -- 29 of 36 -- $404 $580 $704 $876 2019 2020 2021 2022 $444 $725 $989 $1,116 2019 2020 2021 2022 $11,084 $14,380 $17,186 $20,937 2019 2020 2021 2022 Sustained strong full-year performance across key growth pillars All growth rates exclude the impact of foreign exchange. $ In millions. Lynparza in collaboration with AstraZeneca. Lenvima in collaboration with Eisai. $1,131 $1,198 $1,532 $1,685 2019 2020 2021 2022 $3,737 $3,938 $5,673 $6,897 2019 2020 2021 2022 $4,393 $4,703 $5,568 $5,550 2019 2020 2021 2022 +6% YOY +27% YOY +16% YOY +28% YOY +18% YOY +27% YOY 30 -- 30 of 36 -- Q4 2022 continuing operations GAAP financial results summary 31 Q4 2022 Q4 2021 Change Change Ex-FX Sales $13.8 $13.5 +2% +8% Operating Expenses $6.5 $5.9 +10% +13% Tax Rate 14.1% 2.2% +11.9pts N/A GAAP EPS $1.18 $1.51 -22% -17% $ in billions, except EPS amounts -- 31 of 36 -- 2022 continuing operations GAAP financial results summary: 32 2022 2021 Change Change Ex-FX Sales $59.3 $48.7 +22% +26% Operating Expenses $23.6 $21.9 +8% +11% Tax Rate 11.7% 11.0% +0.7pts N/A GAAP EPS $5.71 $4.86 +17% +21% $ in billions, except EPS amounts -- 32 of 36 -- 2022 continuing operations non-GAAP financial results summary: Delivered strong revenue and EPS growth 2022 2021 Change Change Ex-FX Sales $59.3 $48.7 +22% +26% Non-GAAP Gross Margin1 74.4% 76.1% -1.7pts -2.1pts Operating Expenses $21.6 $21.0 +3% +6% Tax Rate 14.2% 12.4% +1.8pts N/A Non-GAAP EPS that excludes certain items 1 $7.48 $5.37 +39% +43% $ in billions, except EPS amounts 33 1. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. -- 33 of 36 -- $10.2 $4.4 $7.0 $2.4 $0.0 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.76 $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 $3.20 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Dollars per share +2% +2% +2% +2% +2% +11% +15% +7% Over the past 12 months Capital investments 2022 to 2026 Commitment to the dividend 34 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% Order of priority +6% E 1. Includes payments reflected in operating cash flow 1 -- 34 of 36 -- Driving value for patients and shareholders by progressing our pipeline 35 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S.: o The FDA granted approval of KEYTRUDA following surgical resection and platinum-based chemotherapy in patients with stage IB, II or IIIA non-small cell lung cancer based on KN-091, as well as accepted submission of Supplemental Biologics License Applications for PADCEV1 + KEYTRUDA to be used in combination as 1L treatment of certain patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy based on KN-869 • In Europe: o Received approval for Lynparza2 in combination with abiraterone and prednisone or prednisolone in certain patients with metastatic castration-resistant prostate cancer based on PROpel • In China: o Received approval for KEYTRUDA in patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment based on KN-522, as well as conditional marketing authorization for LAGEVRIO in adult patients with mild to medium COVID-19 infection and a high risk of progressing to severe cases • In Japan: o Completed submission of KN-170/KN-A33 in patients with relapsed or refractory primary mediastinal large B-cell lymphoma 1. In collaboration with Astellas and Seagen. Padcev is a registered trademark of Seagen and Agensys. 2. In collaboration with AstraZeneca. • Announced with partner Moderna, positive topline results from Phase 2b KN-942 trial evaluating mRNA- 4157/V940, an investigational personalized mRNA cancer vaccine in combination With KEYTRUDA • Announced positive topline results from Phase 3 KN- 859 trial evaluating KEYTRUDA in combination with chemotherapy for 1L treatment in patients with HER2- negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma • Presented data across broad hematology pipeline and portfolio at ASH, including for favezelimab (MK-4280), zilovertamab vedotin (MK-2140), nemtabrutinib (MK- 1026) and KEYTRUDA • Announced publication of updated systematic literature review examining the global impact and effectiveness of GARDASIL across 138 studies • Initiated Phase 3 studies for MK-1026 in hematologic malignancies -- 35 of 36 -- Phase 2 Phase 3 Under regulatory review Oncology V181 Dengue Fever Virus Vaccines Infectious diseases MK-8189 4 Schizophrenia Neuroscience Gefapixant (MK-7264) Cough (US, EU) General medicine General medicine As of February 17, 2023 V114 Pneumococcal Vaccine, pediatric (JPN) Vaccines Infectious diseases Oncology Oncology MK-1942 Treatment Resistant Depression MK-6024 (efinopegdutide) NASH MK-7075 (miransertib) Overgrowth Syndrome MK-8591B (islatravir+MK-8507)1 HIV-1 Infection MK-8591D (islatravir+lenacapavir)2 HIV-1 Infection KEYTRUDA (MK-3475) Biliary Tract CSCC (EU) Gastric (EU) Hepatocellular (EU) Mesothelioma Ovarian Prostate SCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-7684A (vibostolimab +pembrolizumab) Melanoma NSCLC SCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies LENVIMA (MK-7902) CRC Esophageal Gastric HNSCC Melanoma NSCLC LYNPARZA (MK-7339) NSCLC SCLC WELIREG (MK-6482) RCC TUKYSA (MK-7119) Breast CRC MK-3475 (pembrolizumab subcutaneous) NSCLC MK-3475A (pembrolizumab +hyaluronidase) NSCLC MK-8591A (doravirine+islatravir)2 HIV-1 Infection LAGEVRIO (MK-4482)3 COVID-19 antiviral KEYTRUDA (MK-3475) 1L Urothelial (US) 2L HCC (US) LA Merkel Cell (US) Adjuvant NSCLC (EU) B-Cell Lymphoma (JPN) LYNPARZA (MK-7339) Metastatic 1L Prostate (US, JPN) MK-0616 Hypercholesterolemia MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease Cardiovascular MK-4830 CRC Esophageal Melanoma NSCLC Ovarian RCC SCLC MK-5684 Prostate MK-5890 (boserolimab) NSCLC SCLC MK-6440 (ladiratuzumab vedotin) Breast Esophageal Gastric HNSCC Melanoma NSCLC Prostate SCLC MK-2870 Neoplasm Malignant KEYTRUDA (MK-3475) Advanced Solid Tumors MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) NSCLC MK-4280A (favezelimab+pembroli zumab) Esophageal Melanoma RCC SCLC WELIREG (MK-6482) Biliary Certain VHL tumors (EU) CRC Endometrial Esophageal HCC Pancreatic Rare Cancers LYNPARZA (MK-7339) Advanced Solid Tumors LENVIMA (MK-7902) Biliary Pancreas Prostate SCLC mRNA-4157/V940 Melanoma MK-7684A (vibostolimab +pembrolizumab) Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Hematological Malignancies Ovarian Prostate TUKYSA (MK-7119) Advanced Solid Tumors Bladder Biliary Cervical Endometrial Gastric NSCLC MK-0482 NSCLC MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC HCC Melanoma SCLC MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies NSCLC Ovarian Pancreas Broad and innovative pipeline to solve significant unmet medical needs 36 Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma MK-7962 (sotatercept) Pulmonary Arterial Hypertension Cardiovascular Infectious diseases LAGEVRIO (MK-4482) COVID-19 antiviral (EU) V116 Pneumococcal vaccine, adult Hospital PREVYMIS (MK-8228) Prophylaxis of CMW in kidney transplant patients -- 36 of 36 --